AR009990A1 - Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen - Google Patents
Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienenInfo
- Publication number
- AR009990A1 AR009990A1 ARP970104749A ARP970104749A AR009990A1 AR 009990 A1 AR009990 A1 AR 009990A1 AR P970104749 A ARP970104749 A AR P970104749A AR P970104749 A ARP970104749 A AR P970104749A AR 009990 A1 AR009990 A1 AR 009990A1
- Authority
- AR
- Argentina
- Prior art keywords
- tace
- disease
- independently selected
- membered heteroaryl
- heteroaryl ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Abstract
Inhibidores no peptídicos de bajo peso molecular de las metaloproteinasas de matriz (por ejemplo, gelatinasas, estromelisinas y colagenasas) y de laenzima conversora de TNF - alfa (TACE, enzima de conversion de factor alfa de necrosis tumoral) que son utiles para el tratamiento de enfermedades en lascuales intervienen estas enzimas, tales como la artritirs, la metástasis y desarrollo de tumores, alangiogénesis, al ulceracion de tejidos, lacicatrizacion anormal de heridas, enfermedad periodontal, enfermedad osea, proteinuria, enfermedad de aneurisma aortico, pérdida degenerativa de cartílagoposterior a lesion traumática de las articulaciones, enfermedades desmielinizantes del sistema nervioso, rechazo de injertos,caquexia, anorexia,inflamacion, fiebre resistencia a la insulina, choque séptico, insuficiencia cardíaca congestiva, enfermedad inflamatoria del sistema nervioso central,enfermedad inflamatoria intestinal, infeccion por HIV, degeneracion macularasociada a la edad, retinopatía diabética, vitreorretinopatía proliferativa,retinopatía de la prematuridad, inflamacion ocular, queratocono, síndrome de Sjogren, miopía, tumores oculares, angiogénesis/ neovascularizacion ocular. Losácidos orto-sulfonamido arilhidroxámicos inhibidores de TACE y MMP están representados por la formula (I) en la cual la porcion de ácido hidroxámico yla porcion sulfonamido están unidas a los carbonos adyacentes del grupo A donde A es un anillo heteroarilo de 5 a 6 miembros con 1 a 3 heteroátomosindependientemente seleccionados entre N, O y S fusionado o un anillo heteroarilo de 5-6 miembros que tiene de 1 a 3 heteroátomos independientementeseleccionados entre N, O y S fusionado o un anillo heteroarilo de 5-6 miembros que tiene de 1 a 3 heteroátomos independientemente seleccionados entre N, O y S
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73200496A | 1996-10-16 | 1996-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR009990A1 true AR009990A1 (es) | 2000-05-17 |
Family
ID=24941797
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP970104749A AR009990A1 (es) | 1996-10-16 | 1997-10-15 | Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen |
Country Status (4)
Country | Link |
---|---|
AR (1) | AR009990A1 (es) |
AU (1) | AU743901B2 (es) |
WO (1) | WO1998016514A1 (es) |
ZA (1) | ZA979235B (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6548524B2 (en) * | 1996-10-16 | 2003-04-15 | American Cyanamid Company | Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors |
WO1998016520A1 (en) * | 1996-10-16 | 1998-04-23 | American Cyanamid Company | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
CN1138760C (zh) * | 1997-10-06 | 2004-02-18 | 惠氏控股公司 | 作为基质金属蛋白酶和tace抑制剂的邻亚磺酰氨基二环杂芳基异羟肟酸的制备和用途 |
US6110929A (en) * | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
GB9919776D0 (en) | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
EP1147085B1 (en) | 1999-01-27 | 2005-11-16 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid derivatives, their preparation and their use as matrix metalloproteinase (mmp) inhibitors / tnf-alpha converting enzyme (tace) inhibitors |
US6200996B1 (en) | 1999-01-27 | 2001-03-13 | American Cyanamid Company | Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors |
US6277885B1 (en) | 1999-01-27 | 2001-08-21 | American Cyanamid Company | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
AR035311A1 (es) * | 1999-01-27 | 2004-05-12 | Wyeth Corp | Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento |
US6313123B1 (en) | 1999-01-27 | 2001-11-06 | American Cyanamid Company | Acetylenic sulfonamide thiol tace inhibitors |
US6762178B2 (en) | 1999-01-27 | 2004-07-13 | Wyeth Holdings Corporation | Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors |
AR022424A1 (es) * | 1999-01-27 | 2002-09-04 | American Cyanamid Co | Compuestos derivados de acidos ortosulfonamido acetilenico e hidroxamico biciclico heteroarilo amido de acido fosfinico como inhibidores tace, composicionfarmaceutica que los comprende y el uso de los mismos para la manufactura de un medicamento |
US6753337B2 (en) | 1999-01-27 | 2004-06-22 | Wyeth Holdings Corporation | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors |
US6340691B1 (en) | 1999-01-27 | 2002-01-22 | American Cyanamid Company | Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors |
US6225311B1 (en) | 1999-01-27 | 2001-05-01 | American Cyanamid Company | Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors |
US6946473B2 (en) | 1999-01-27 | 2005-09-20 | Wyeth Holdings Corporation | Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors |
KR20020079882A (ko) * | 2000-02-21 | 2002-10-19 | 아스트라제네카 아베 | 아릴피페라진 및 아릴피페리딘 및 금속단백질분해효소억제제로서의 그의 용도 |
CA2396965C (en) | 2000-02-21 | 2010-03-16 | Astrazeneca Ab | Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases |
US6465508B1 (en) | 2000-02-25 | 2002-10-15 | Wyeth | Preparation and use of ortho-sulfonamido aryl hydroxamic acids as matrix metalloproteinase inhibitors |
AR027943A1 (es) * | 2000-02-25 | 2003-04-16 | Wyeth Corp | Acidos orto-sulfonamido aril hidroxamicos como inhibidores de metaloproteinasa de matriz y preparacion de los mismos |
AU2001250571A1 (en) * | 2000-04-28 | 2001-11-12 | P.N. Gerolymatos S.A. | Treatment of pathological conditions influenced by the action of matrix metalloproteinases (mmps) using clioquinol |
US6576644B2 (en) | 2000-09-06 | 2003-06-10 | Bristol-Myers Squibb Co. | Quinoline inhibitors of cGMP phosphodiesterase |
US6436629B1 (en) * | 2000-10-27 | 2002-08-20 | The Regents Of The University Of California | Modulating angiogenesis |
GB0119474D0 (en) | 2001-08-09 | 2001-10-03 | Astrazeneca Ab | Compounds |
WO2003032999A1 (en) * | 2001-10-12 | 2003-04-24 | Warner-Lambert Company Llc | Alkyne matrix metalloproteinase inhibitors |
US6962922B2 (en) | 2001-10-12 | 2005-11-08 | Warner-Lambert Company Llc | Alkynylated quinazoline compounds |
EP1442018A1 (en) * | 2001-10-31 | 2004-08-04 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Novel anticancer compounds |
BR0213736A (pt) | 2001-11-01 | 2004-10-19 | Wyeth Corp | ácidos hidroxâmicos de sulfonamida de arila alênica como metaloproteinase matriz e inibidores de tace |
US6747147B2 (en) | 2002-03-08 | 2004-06-08 | Warner-Lambert Company | Oxo-azabicyclic compounds |
US6894057B2 (en) | 2002-03-08 | 2005-05-17 | Warner-Lambert Company | Oxo-azabicyclic compounds |
CA2494048A1 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | 4-hydroxyquinoline derivatives as matrix metalloproteinase inhibitors |
US7491718B2 (en) | 2002-10-08 | 2009-02-17 | Abbott Laboratories | Sulfonamides having antiangiogenic and anticancer activity |
US20040157836A1 (en) * | 2002-10-08 | 2004-08-12 | Comess Kenneth M. | Sulfonamides having antiangiogenic and anticancer activity |
US7098241B2 (en) | 2002-12-16 | 2006-08-29 | Hoffmann-La Roche Inc. | Thiophene hydroxamic acid derivatives |
WO2005021489A2 (en) | 2002-12-23 | 2005-03-10 | Wyeth Holdings Corporation | Acetylenic aryl sulfonate hydroxamic acid tace and matrix metalloproteinase inhibitors |
US20080207673A1 (en) * | 2005-05-04 | 2008-08-28 | Michel Xilinas | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins |
JP5588339B2 (ja) * | 2007-06-25 | 2014-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化学化合物 |
JP2012513464A (ja) | 2008-12-23 | 2012-06-14 | ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク | ホスホジエステラーゼ阻害剤及びその使用 |
FR2947268B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
FR2947270B1 (fr) | 2009-06-30 | 2011-08-26 | Galderma Res & Dev | Nouveaux composes benzene-sulfonamides, leur procede de synthese et leur utilisation en medecine ainsi qu'en cosmetique |
US8513421B2 (en) | 2010-05-19 | 2013-08-20 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
US20140275108A1 (en) | 2013-03-15 | 2014-09-18 | Galderma Research & Development | Novel benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine as well as in cosmetics |
IL237852A0 (en) | 2015-03-19 | 2016-03-24 | Yeda Res & Dev | Antibodies against amphigoline, medical preparations containing them and their use |
WO2017117130A1 (en) | 2015-12-28 | 2017-07-06 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells |
EP3199534B1 (en) | 2016-02-01 | 2018-09-05 | Galderma Research & Development | Benzenesulfonamide compounds, method for synthesizing same, and use thereof in medicine and cosmetics |
US20210393632A1 (en) | 2018-10-04 | 2021-12-23 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5455258A (en) * | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
WO1998016520A1 (en) * | 1996-10-16 | 1998-04-23 | American Cyanamid Company | The preparation and use of ortho-sulfonamido heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
-
1997
- 1997-10-08 AU AU49806/97A patent/AU743901B2/en not_active Ceased
- 1997-10-08 WO PCT/US1997/018281 patent/WO1998016514A1/en active Application Filing
- 1997-10-15 ZA ZA979235A patent/ZA979235B/xx unknown
- 1997-10-15 AR ARP970104749A patent/AR009990A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
ZA979235B (en) | 1999-04-15 |
WO1998016514A1 (en) | 1998-04-23 |
AU743901B2 (en) | 2002-02-07 |
AU4980697A (en) | 1998-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR009990A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos biciclicos como inhibidores de la metaloproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos, y composiciones farmaceuticas que los contienen | |
AR008677A1 (es) | Acidos orto-sulfonamido heteroaril hidroxamicos como inhibidores de la metalproteinasa de matriz y tace, uso de dichos compuestos para prepararmedicamentos y composicion farmaceutica que los contiene | |
AR008676A1 (es) | Acidos beta-sulfonamido hidrosamicos como inhibidores de la metaloproteinasa de matriz y tace, uso de los mismos en la preparacion de unmedicamento y una composicion farmaceutica que los contienen | |
AR009382A1 (es) | Derivados de acidos orto-sulfonamido aril hidroxamicos como inhibidores de la metaloproteinasa de matriz y tace, composiciones que los contienen y uso delos mismos para la preparacion de un medicamento. | |
RU2324684C2 (ru) | Пиримидиновые производные | |
DK0871439T3 (da) | Substituerede (aryl, heteroaryl, arylmethyl eller heteroarylmethyl) hydroxamsyreforbindelser | |
ATE286501T1 (de) | Pyrimidinderivate | |
MXPA05008148A (es) | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transformante (tgf). | |
BR9813651A (pt) | Compostos antipicornavirais e métodos para o seu uso e preparação | |
EA200600975A1 (ru) | Конденсированные гетероциклические соединения, применимые для лечения ожирения и расстройств центральной нервной системы | |
EA200601194A1 (ru) | Новые производные бензофурана, используемые для профилактики или лечения нарушений, связанных с 5-ht-рецептором | |
ES2038172T3 (es) | Procedimiento para preparar carboxamidas heterociclicas. | |
DE3879873T2 (de) | Physiologisch aktive substanzen, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zusammensetzungen. | |
AR032607A1 (es) | Composiciones farmaceuticas que contienen sales de hidroxieicosatetraenoato, y el uso de las mismas para la manufactura de un medicamento para el tratamiento de desordenes del ojo seco | |
FR2800735B1 (fr) | Nouvelles aralkyle-1,2-diamines possedant une activite calcimimetique et leur mode de preparation | |
AR022423A1 (es) | Compuestos derivados de acidos 2,3,4,5-tetrahidro-1h-[1,4]benzodiazepina-3-hidroxamicos, composicion farmaceutica que los comprenden, y el uso de losmismos para la manufactura de un medicamento | |
MA28340A1 (fr) | Derives de l'acide 7- amino-4- quinolone-3-carboxylique substitues par un groupe cycloalkyle, methode pour leur production et leur utilisation en tant que medicaments | |
SE8406201L (sv) | Penicillansyraderivat | |
AR041481A1 (es) | Derivados de acido arilpropionico-oxazol y su uso como agonistas de ppar | |
BR9909267A (pt) | C11 oximila e prostaglandinas hidroxilamino úteis como medicamentos | |
AR022405A1 (es) | Derivados de acido piroglutamico y compuestos relacionados que inhiben la adhesion de leucocitos intermediada por vla-4, composiciones farmaceuticas y eluso de los mismos para la manufactura de agentes y de medicamentos | |
IL166103A0 (en) | Pyrrolidine derivatives and their use | |
NO155135C (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-amino-1-benzoxepinderivater. | |
ATE73807T1 (de) | Neue benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte. | |
KR102042411B1 (ko) | 데커신 유도체를 포함하는 결핵 예방 또는 치료용 조성물 |